Avtor/Urednik		Saba, Nabil F.; Mody, Mayur D.; Tan, Elaine S.; Gill, Harpaul S.; Rinaldo, Alessandra; Takes, Robert P.; Strojan, Primož; Hartl, Dana M.; Vermorken, Jan B.; Haigentz, Missak; Ferlito, Alfio
Naslov		Toxicities of systemic agents in squamous cell carcinoma of the head and neck (SCCHN)
Tip		članek
Vol. in št.		, št. Vol. 115
Leto izdaje		2017
Obseg		str. 50-58
ISSN		1040-8428 - Critical reviews in oncology/hematology
Jezik		eng
Abstrakt		Squamous cell carcinoma of the head and neck (SCCHN) is a difficult to treat malignancy and represents the seventh most common cancer worldwide. Systemic therapy has a critical role in the treatment of locally advanced and recurrent/metastatic disease. Cytotoxic chemotherapy has been primarily used along with radiation and surgery, with cisplatin being the standard of care choice of therapy. When contraindications to cisplatin exist, other agents such as carboplatin, taxanes, 5-fluorouracil, and cetuximab are used. Similarly, in the advanced or metastatic setting, platinum agents, taxanes and cetuximab have been predominantly utilized. With the recent approval of novel agents such as pembrolizumab and nivolumab, and their distinct toxicity profiles, an understanding of the potential sequelae of the different systemic agents is essential to the careful selection of agents in the advanced disease setting. Going forward, choosing novel agents will be weighed against traditional chemotherapy, and understanding the toxicities at stake is critical in this process. In addition to providing an overview of the toxicity profile of the different systemic agents, we also provide a perspective into the future of SCCHN treatment.
Proste vsebinske oznake		rak glave in vratu imunoterapija ploščatocelični rak kemoterapija neželeni učinki head and neck cancer immunotherapy squamous cell carcinoma chemotherapy adverse events